Neovascular-targeted immunoconjugates
Abstract
(57) A summary and subject The immunity complex for treating cancer, rheumatoid arthritis, the macular degeneration of an exudative form, and the disease relevant to a blood vessel rebirth like an atherosclerotic cardiovascular disease is offered. Solution means The immunity complex concerned typically, When Fc domain of human IgG1 immunoglobulin including a hinge or a patient is medicated, it consists of other effector domains (one or more than it) which can induce a cytolytic property immune response or a cell damage action to a target cell. The by which, as for the effector domain, an alanine or serine *344 were replaced for ricin *341 by the alanine -- blood coagulation is not made to start although it combines with a tissue factor by the high affinity and singularity like a VII factor -- the -- it is compounded with the target domain containing a VII factor mutant.
Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
25 members in 12 offices
Priority claims1
| Document | Office | Kind | Date |
|---|---|---|---|
| 14216199 | United States of America | P |
Members25
| Document | Office | Kind | |
|---|---|---|---|
| CA2377381A1 | Canada | A1 | |
| WO0102439A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU5614900A | Australia | A | |
| EP1198479A1 | European Patent Office (EPO) | A1 | |
| JP2003504315A | Japan | A | |
| AU775621B2 | Australia | B2 | |
| EP1198479A4 | European Patent Office (EPO) | A4 | |
| US6924359B1 | United States of America | B1 | |
| US2005214298A1 | United States of America | A1 | |
| EP1198479B1 | European Patent Office (EPO) | B1 | |
| AT398633TThis record | Austria | T | |
| DE60039240D1 | Germany | D1 | |
| PT1198479E | Portugal | E | |
| DK1198479T3 | Denmark | T3 | |
| ES2307517T3 | Spain | T3 | |
| US7858092B2 | United States of America | B2 | |
| US7887809B1 | United States of America | B1 | |
| US2011117114A1 | United States of America | A1 | |
| US8071104B2 | United States of America | B2 | |
| US2012082686A1 | United States of America | A1 | |
| JP2012255032A | Japan | A | |
| US8388974B2 | United States of America | B2 | |
| CA2377381C | Canada | C | |
| CY1110394T1 | Cyprus | T1 | |
| JP5745486B2 | Japan | B2 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Publication of translation of european patent specificationUEP | UEP |
Numbers
- Application
- 941443
Titles2
- German
- NEOVASKULÄR GERICHTETE IMMUNKONJUGATE
- English
- NEOVASCULAR IMMUNOJUGATE
Classification
- CPC, 10
- C07K16/3053
- A61K2039/505
- A61P9/10
- C07K2317/622
- A61P19/02
- C07K2319/00
- A61P27/02
- C07K2319/30
- A61P29/00
- A61P35/00
- IPC, 15
- A61K35 76
- A61K38 00
- A61K38 43
- A61K39 00
- A61K39 395
- A61K47 48
- A61K48 00
- A61P19 02
- A61P29 00
- A61P35 00
- A61P9 10
- C07K14 47
- C07K16 00
- C07K16 30
- C12N15 09